Back to stewardship basics: Treatment of highly resistant Gram-negative infections
Several agents have been developed to target gram-negative organisms that have developed specific resistance profiles. The appropriate use of each of these agents can be highly nuanced and dependent upon availability, patient characteristics, and development of resistance mechanisms. Guidance documents have been published to help practitioners choose the best therapy for patients that successfully treats the infection while also preserving last-line therapies, but the practical application can be challenging. This presentation will highlight three different patient cases that result in clinically guided treatment recommendations to help pharmacist learn when to best use each of the available agents.
1. Define key recommendations presented in the 2022 IDSA Guidance for the treatment of resistant gram-negative bacterial infections
2. Recognize differences in treatment options for the treatment of resistant gram-negative bacterial infections
3. Select the best treatment option for resistant gram-negative bacterial infections based on patient-specific factors
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Brian Bohn, PharmD, BCPS
Clinical Pharmacy Specialist- Infectious Diseases
Barnes Jewish Hospital
Trang Trinh, PharmD, MPH, BCPS, BCIDP
Associate Professor of Clinical Pharmacy
UCSF School of Pharmacy
Yang Zhao, PharmD, BCPS
Clinical Pharmacy Specialist – Infectious Diseases
Sentara Norfolk General Hospital
Sr. Pharmacy Executive
John Schoen, PharmD, BCPS
Sr. Clinical Manager of Drug Information
Joseph M. Geskey, DO, MBA, MS-PopH
DO, MBA, MS-PopH
Principal, Data Science & Member Insights • Vizient Inc
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Tran Trinh – Will be discussing off-label use of antibiotics
Yang Zhao – Will be discussing combination treatment approaches 2/avibactam for NDM and steno infections
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-0000-22-160-L01-P
Vizient, Inc. designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 1.00 ACPE Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General CE – Attendance